{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:03:22Z","timestamp":1793865802874,"version":"4.6.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ygyno.2024.01.034","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T18:24:43Z","timestamp":1707330283000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis"],"prefix":"10.1016","volume":"184","author":[{"given":"Sahana","family":"Somasegar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravali A.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Dorigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2024.01.034_bb0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155 Suppl 1","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0010","series-title":"Key statistics for ovarian cancer","author":"American Cancer Society","year":"2023"},{"issue":"10","key":"10.1016\/j.ygyno.2024.01.034_bb0015","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"126","author":"Henley","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0020","series-title":"Berek and Hacker\u2019s Gynecologic Oncology","article-title":"Epithelial ovarian, fallopian tube, and peritoneal cancer","author":"Berek","year":"2020"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0025","series-title":"Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligaments. Atlas of Tumor Pathology. Third Series","author":"Scully","year":"1998"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ygyno.2024.01.034_bb0035","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.01.034_bb0040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.01.034_bb0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.10.019","article-title":"The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)","volume":"144","author":"Matz","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2024.01.034_bb0050","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/0895-4356(94)90089-2","article-title":"A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer","volume":"47","author":"Chu","year":"1994","journal-title":"J. Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.ygyno.2024.01.034_bb0055","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-Cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0060","author":"National Cancer Institute Surveillance"},{"issue":"6","key":"10.1016\/j.ygyno.2024.01.034_bb0065","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jamasurg.2018.0501","article-title":"Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database","volume":"153","author":"Doll","year":"2018","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0070","series-title":"Summary Stage 2018: Codes and Coding Instructions","year":"2023"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0075","series-title":"International classification of diseases for oncology (ICD-O), 3rd ed., 1st revision","author":"World Health Organization","year":"2013"},{"issue":"7","key":"10.1016\/j.ygyno.2024.01.034_bb0080","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0085","unstructured":"National Cancer Institute. Joinpoint: Software to detect trends. Retrieved from https:\/\/surveillance.cancer.gov\/joinpoint\/."},{"issue":"49","key":"10.1016\/j.ygyno.2024.01.034_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","article-title":"Cancer survival: an overview of measures, uses, and interpretation","volume":"2014","author":"Mariotto","year":"2014","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0095","unstructured":"\u201cStandard Populations (Millions) for Age-Adjustment \u2013 Seer Population Datasets.\u201d SEER, seer.cancer.gov\/stdpopulations\/. Accessed 13 Jan. 2024."},{"issue":"14","key":"10.1016\/j.ygyno.2024.01.034_bb0100","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2000.18.14.2728","article-title":"Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy","volume":"18","author":"Lu","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2024.01.034_bb0105","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2024.01.034_bb0110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/gyno.2002.6779","article-title":"Pathologic findings in prophylactic oophorectomy specimens in high-risk women","volume":"87","author":"Leeper","year":"2002","journal-title":"Gynecol. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2024.01.034_bb0115","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2024.01.034_bb0120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.ygyno.2024.01.034_bb0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ygyno.2004.10.017","article-title":"Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?","volume":"96","author":"Olivier","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2024.01.034_bb0130","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/ejhg.2009.60","article-title":"Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk","volume":"17","author":"Evans","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"issue":"29","key":"10.1016\/j.ygyno.2024.01.034_bb0135","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199","volume":"32","author":"Sherman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"issue":"3","key":"10.1016\/j.ygyno.2024.01.034_bb0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA."},{"issue":"9574","key":"10.1016\/j.ygyno.2024.01.034_bb0150","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the million women study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.ygyno.2024.01.034_bb0155","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/bjc.2012.397","article-title":"Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study","volume":"107","author":"Trabert","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0160","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.fertnstert.2004.03.013","article-title":"Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study","volume":"82","author":"Pike","year":"2004","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0165","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/1055-9965.EPI-12-1030-T","article-title":"Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer","volume":"22","author":"Pearce","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0170","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(94)90749-8","article-title":"Parity, age at first childbirth, and risk of ovarian cancer","volume":"344","author":"Adami","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0175","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ejca.2010.10.004","article-title":"Does the time interval between first and last birth influence the risk of endometrial and ovarian cancer?","volume":"47","author":"Bevier","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0180","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/aje\/kwn006","article-title":"Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women","volume":"167","author":"Moorman","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/aje\/kwf048","article-title":"Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study","volume":"156","author":"Riman","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0190","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1054\/bjoc.2000.1596","article-title":"Menstrual and reproductive factors in relation to ovarian cancer risk","volume":"84","author":"Titus-Ernstoff","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0195","first-page":"42","article-title":"Timing of pregnancy and the risk of epithelial ovarian cancer","volume":"12","author":"Whiteman","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prevent Publ Am Assoc Cancer Res Am Soc Prevent Oncol"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0200","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/oxfordjournals.aje.a116427","article-title":"Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group","volume":"136","author":"Whittemore","year":"1992","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2024.01.034_bb0210","first-page":"1","article-title":"Use of contraception in the United States: 1982-2008","volume":"29","author":"Mosher","year":"2010","journal-title":"Vital Health Stat."},{"issue":"10290","key":"10.1016\/j.ygyno.2024.01.034_bb0215","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2024.01.034_bb0220","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cncr.22371","article-title":"Development of an ovarian cancer symptom index: possibilities for earlier detection","volume":"109","author":"Goff","year":"2007","journal-title":"Cancer."},{"issue":"9","key":"10.1016\/j.ygyno.2024.01.034_bb0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.NAJ.0000360309.08701.73","article-title":"Original research: women\u2019s awareness of ovarian cancer risks and symptoms","volume":"109","author":"Lockwood-Rayermann","year":"2009","journal-title":"Am. J. Nurs."},{"issue":"2","key":"10.1016\/j.ygyno.2024.01.034_bb0230","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2018.01.030","article-title":"Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US","volume":"149","author":"Liao","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2024.01.034_bb0235","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/jnci\/djx263","article-title":"Reported incidence and survival of fallopian tube carcinomas: a population-based analysis from the north American Association of Central Cancer Registries","volume":"110","author":"Trabert","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2024.01.034_bb0240","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12885-018-4498-z","article-title":"Changes in ovarian cancer survival during the 20 years before the era of targeted therapy","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2024.01.034_bb0245","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.01.034_bb0250","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10106","key":"10.1016\/j.ygyno.2024.01.034_bb0255","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ygyno.2024.01.034_bb0260","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:52:35Z","timestamp":1726246355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":52,"alternative-id":["S0090825824000490"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.034","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}